As the cannabis market transitions from illegal to legal it presents a unique challenge to regulators.
How does a well-established, multi-billion £/$/€ industry operating in the shadows fit into the prevailing pharmaceutical regulatory paradigm? What challenges do operators face, and can there be learnings on both sides of the debate?
Alex talks to some of these issues using his personal experience over the past 3 years.
More Information
Advertisement
Advertisement